Table 2 Fold change in CD20 in B-CLL... | American Society of Hematology

Table 2

Fold change in CD20 in B-CLL cells treated with 0.5 μM lenalidomide compared with vehicle

Patient no.	% of CD20⁺ cells		MFIR
Patient no.	Vehicle	Lenalidomide	Vehicle	Lenalidomide
1	71	59	6	4
2	83	66	7	5
3	90	77	139	96
4	57	28	6	3
5	78	56	61	4
6	85	70	7	5
7	56	40	4	2
8	91	61	ND	ND
9	75	52	6	5
10	97	83	40	40
11	91	76	9	6
12	53	37	ND	ND
13	77	62	ND	ND
14	91	60	12	5
15	73	26	182	32
16	98	78	446	152
17	97	37	411	65
18	70	60	105	88

Patient no.	% of CD20⁺ cells		MFIR
Patient no.	Vehicle	Lenalidomide	Vehicle	Lenalidomide
1	71	59	6	4
2	83	66	7	5
3	90	77	139	96
4	57	28	6	3
5	78	56	61	4
6	85	70	7	5
7	56	40	4	2
8	91	61	ND	ND
9	75	52	6	5
10	97	83	40	40
11	91	76	9	6
12	53	37	ND	ND
13	77	62	ND	ND
14	91	60	12	5
15	73	26	182	32
16	98	78	446	152
17	97	37	411	65
18	70	60	105	88

MFIR indicates relative mean fluorescence intensity; and ND, not determined.